<DOC>
	<DOCNO>NCT01101581</DOCNO>
	<brief_summary>The goal study evaluate new approach immunotherapy NHL combine two antibody , veltuzumab epratuzumab . For treatment , epratuzumab also attach radioactive isotope call 90yttrium ( 90Y-epratuzumab ) . Veltuzumab 90Y-epratuzumab attack different area lymphoma cell . Because , treatment combination may provide effective treatment NHL either veltuzumab 90Y-epratuzumab give alone .</brief_summary>
	<brief_title>Study Veltuzumab 90Y-Epratuzumab Relapsed/Refractory , Aggressive NHL</brief_title>
	<detailed_description>The treatment portion study consist study drug administration week four week row ( total 4 treatment day ) . Patients return interval 12 week blood sample evaluation see disease respond monitor adverse effect relate treatment . Some blood test may need repeat least time and/or abnormal finding earlier evaluation resolve . Otherwise , patient continue evaluate every 3 month two year , every 6 month 5 year disease worsens . Participation study end NHL disease worsens .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Aggression</mesh_term>
	<mesh_term>1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid</mesh_term>
	<criteria>Male female , &gt; 18 year old Histological diagnosis CD20+ Bcell NHL , DLBCL aggressive lymphoma WHO lymphoma criterion include mantle cell lymphoma transform follicular lymphoma . Failed least one prior standard treatment regimen NHL If DLBCL , either receive , ineligible refuse highdose chemotherapy stem cell transplant Measurable NHL disease CT , least one lesion &gt; 1.5 cm one dimension Adequate performance status ( &gt; 70 Karnofsky scale , 01 ECOG ) * estimate life expectancy least 6 month Laboratory parameter : Adequate hematology ( Hemoglobin &gt; /= 10 g/dL , ANC &gt; /= 1.5 ´ 109/L , platelet &gt; /=100 x 109/L ) without ongoing transfusional support Adequate renal liver function ( creatinine bilirubin &lt; /= 1.5 x IULN ; AST ALT &lt; /= 2.5 x IULN ) Otherwise , &lt; Grade 1 toxicity study entry NCI CTC version 3.0 . 3 month beyond prior rituximab veltuzumab treatment , 12 week beyond autologous stem cell transplant 4 week beyond chemotherapy , experimental treatment , radiation therapy index lesion ( ) . Screened hepatitis B ( time limit ) negative test include NCCN guideline ( hepatitis B surface antigen/antibodies , core antigen/antibodies , hepatitis B eantigen ) . Patients childbearing potential must willing practice birth control study least 12 week last veltuzumab infusion ; woman childbearing potential must negative urine serum pregnancy test enter study . Ability provide sign , informed consent Pregnant lactate woman . Women childbearing potential require negative pregnancy test NCI CTC Grade 3 4 infusion reaction prior antiCD20 antibody ( rituximab , veltuzumab , etc . ) A know antiantibody response prior antiCD20 antibody ( HACA positive , HAHA positive , etc ) Prior radioimmunotherapy , include Zevalin Bexxar . Prior highdose chemotherapy peripheral blood stem cell transplant . Prior therapy human humanize monoclonal antibody , unless HAHA test negative Primary CNS lymphoma , HIV lymphoma transform lymphoma , presence symptomatic CNS metastases carcinomatous meningitis . Rituximab veltuzumab resistant , define progress within 6 month prior rituximab veltuzumab treatment . Bulky disease CT , define single mass &gt; 10 cm great diameter Bone marrow involvement ≥25 % Prior external beam radiation therapy &gt; 30 % bone marrow . Pleural effusion positive cytology lymphoma Patients know HIV positive , hepatitis B positive , hepatitis C positive Known autoimmune disease presence autoimmune phenomenon . Evidence infection require antibiotic within 7 day . Use systemic corticosteroid within 2 week , except low dose regimen ( prednisone , &lt; 20 mg/day , equivalent ) may continue unchanged . Prior malignancy ( nonmelanoma skin cancer carcinoma situ cervix ) unless disease free 5 year . Prior malignancy le 5year diseasefree interval , exclude nonmelanoma skin cancer carcinoma situ cervix . Other concurrent medical psychiatric condition , Investigator 's opinion , may likely confound study interpretation prevent completion study procedure followup examination</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Diffuse Large cell NHL</keyword>
	<keyword>Mantle cell NHL</keyword>
	<keyword>Lymphoblastic lymphoma</keyword>
	<keyword>Diffuse mixed cell lymphoma</keyword>
	<keyword>Diffuse large cell lymphoma</keyword>
	<keyword>large noncleaved cell lymphoma</keyword>
</DOC>